Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors

被引：26

作者：

Bendell, Johanna ^{[1
]}

Bauer, Todd ^{[1
]}

Patel, Manish ^{[2
]}

Falchook, Gerald ^{[3
]}

Karlix, Janet L. ^{[4
]}

Lim, Emerson ^{[5
]}

Mugundu, Ganesh ^{[6
]}

Mitchell, Patrick D. ^{[6
]}

Pouliot, Gayle P. ^{[6
]}

Moorthy, Ganesh ^{[6
]}

Linghu, Bolan ^{[6
]}

McGrath, Lara ^{[6
]}

Harrop, Bryony ^{[6
]}

Shao, Wenlin ^{[6
]}

Drake, Charles G. ^{[5
]}

Sachsenmeier, Kris ^{[6
]}

Merchant, Melinda S. ^{[6
]}

机构：

[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[2] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[3] Hlth One, Sarah Cannon Res Inst, Denver, CO USA

[4] Sarah Cannon Dev Innovat, Nashville, TN USA

[5] Columbia Univ, New York, NY USA

[6] AstraZeneca, Waltham, MA USA

来源：

关键词：

D O I：

10.1158/1538-7445.AM2019-CT026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT026

引用

页数：2